| abstract |
The use of inert gas krypton and / or xenon as active ingredients in a dosage form having an antiviral activity, such as a pharmaceutical composition, or a biologically active additive having an antiviral effect for enteral or parenteral administration, or for applications, in an amount of from 2% to 99% of the maximum possible saturation of the dosage form of krypton and / or xenon, which is suitable for the preparation, storage or use of this pharmaceutical composition, or a biologically active additive in the form of solid or soft, or liquid or gaseous dosage forms for enteral or parenteral administration or for applications. |